Replies to post #118321 on Biotech Values

[DewDiligence]

NVS, ABT, and PFE are strong beneficiaries of The Global Demographic Tailwind that I favor based on their low valuations. Other Big Pharma (BMY being a notable exception) are also beneficiaries of TGDT, but they are less attractive than the three names above, IMO, for one reason or another.